Page 1 sur 3.
HalioDx SAS, the immuno-oncology diagnostic company pioneering the immunological diagnosis of cancers, today announced...
COLONTOWN University Launches Secure Platform for Colorectal Cancer Patients
HalioDx SAS, the immuno-oncology...
HalioDx SAS, la société de diagnostic en immuno-oncologie, a annoncé aujourd'hui que son fondateur scientifique,...
Read the entire Press Release (in French only) here
HalioDx SAS, the immuno-oncology diagnostic company, today announced that, at the European Society of Medical OncologyV...
HalioDx SAS, the immuno-oncology diagnostic company, today announced that it has entered into a Collaboration Agreement...
HalioDx SAS, the immuno-oncology diagnostic company, today announced that Immunoscore® has been included in the 2020...
Considering the recent evolution of the COVID-19 situation, HalioDx has actioned a business continuity plan aimed at...
Marseille, France, March 5, 2020, 1:45 PM CET - The World Health Organization (WHO), in its latest edition of the...
Five major private medical insurances in the UK cover Immunoscore® test for all their patients with localised colon...
OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), a clinical-stage biotechnology company focused on developing...
Kite to Leverage HalioDx’s Immunoscore® Solutions to Understand Tumor Microenvironment and Guide Cancer Cell Therapies...
HalioDx is very proud to share this great news!